In a recent discussion, a neurologist outlined several key areas of focus for migraine research and patient advocacy heading into 2025. Among the priorities are the exploration of new neuropeptides and the completion of neurotoxin trials, with hopes for positive outcomes. A significant emphasis is placed on post-traumatic headache, an area that has seen limited research in the past, and the development of methods to diagnose concussions within minutes of injury, a project slated for launch in 2025.
Biomarkers represent another critical area of interest. The goal is to identify biomarkers that not only facilitate the specific diagnosis of migraines but also predict patient responses to various treatments. This could enable more personalized treatment plans, distinguishing between patients who may benefit from CGRP drugs and those who might respond better to PACAP-targeted therapies. Despite the challenges encountered so far, there is optimism that 2025 could mark a turning point in this research.
Additionally, the neurologist highlighted the importance of working closely with migraine and headache advocacy organizations. With over 30 such groups in the United States, there is a concerted effort to bring these organizations together to discuss collective strategies for patient advocacy. This initiative is supported by secured funding and aims to address the significant gap in care, as less than half of migraine sufferers in the U.S. currently receive a proper diagnosis and treatment. The focus is on overcoming socioeconomic barriers, reaching patients in rural areas, and improving access to specialized care, with the hope of making substantial progress in the next couple of years.
